Indivior Grows Its Market Presence with Inclusion in Russell 2000® Index

Indivior's Significant Leap into U.S. Markets

Indivior PLC, a key player in the pharmaceutical industry focused on treating opioid use disorders (OUD), has made a noteworthy stride by being added to the U.S. Russell 2000® Index effective immediately after the U.S. market opened on June 30, 2025. This inclusion is part of the annual reconstitution of the Russell indexes and positions Indivior as a significant participant in the small-cap market segment.

Understanding the Russell Indexes

The Russell 2000® Index is an essential measure that represents the performance of the smallest 2,000 stocks in the Russell 3000® Index, which encompasses the 4,000 largest stocks in the U.S. As of April 30, stocks are ranked based on their total market capitalization to ensure the index maintains its relevance to investors and market trends. For Indivior, the Indivior stock not only secured its place in the Russell 2000® Index but also gained automatic membership in the relevant growth and value indexes, enhancing its investment profile.

This annual reconstitution helps investment managers and funds align their portfolio strategies with the ever-evolving market landscape, considering that about $10.6 trillion in assets are benchmarked against the U.S. Russell indexes. The adjustments ensure that investors can manage their investments with accurate and relevant data.

Indivior's Commitment to Growth

Commenting on this development, Joe Ciaffoni, CEO of Indivior, expressed enthusiasm about the company's inclusion in these notable indexes. Ciaffoni emphasized, "Indivior's inclusion in the U.S. Russell indexes further aligns our capital markets presence with our growing U.S. business profile. In 2024, 85% of our net revenue was generated in the U.S., predominantly from SUBLOCADE®, our first-in-class, long-acting injectable medication for the treatment of opioid use disorder. We are committed to building our U.S. presence and increasing value for our stakeholders."

This year marked an incredible milestone for Indivior, as the company leveraged its robust portfolio and focused on developing innovative treatment options for OUD. SUBLOCADE® has been a flagship product, illustrating Indivior's commitment to addressing the opioid crisis with effective and accessible treatments. The fact that such a significant portion of their revenue comes from the U.S. market underscores their strategic focus and operational success.

The Impact of the Russell Membership

Joining the Russell indexes allows Indivior to enhance its visibility among institutional investors, many of whom rely on these benchmarks for stable investment strategies. Inclusion may also lead to increased share liquidity and a potential rise in stock price as new investors take notice. The Russell indexes serve as guideposts for performance evaluation, which could prove advantageous for Indivior as they expand their influence in the pharmaceutical sector.

The Russell 2000® Index is not just a recognition, but also a strategic opportunity for Indivior to align its goals with the expectations of the investment community, emphasizing the importance of transparency and performance in their journey ahead.

Conclusion

Indivior’s addition to the U.S. Russell 2000® Index marks a pivotal moment for the company, reflecting its growing prominence within the pharmaceutical industry. With a dedicated focus on combating the opioid crisis and an expanding market share in the U.S., Indivior appears set for a promising future. Investors and stakeholders alike will be keen to observe the impact of this inclusion in the months to come and how it shapes Indivior’s ongoing efforts to transform OUD treatment across the globe.